

231 01 C

+313ht

PROTECTION REIMAGINED

Supervision of the second seco

Year in Review



"We concluded a year of major achievements with the most notable being the divestiture of our Sexual Wellness business. Organic growth improved and we developed detailed plans to realise further significant value from our transformation program. We have also put in place our CEO and Board succession plans as we prepare for the future." Glenn L L Barnes, Chairman

"Ansell continues to challenge itself, and the focus on growing our industry leading brands is showing clear evidence of success. The portfolio review that led to the sale of the Sexual Wellness business also identified significant opportunity to accelerate the performance of the Company's continuing businesses. The aim is to achieve this through a transformation program and continued investment in the Ansell business. I'm very proud of the staff in what has been an impressive year, and I'm excited by the prospects going forward."

Magnus Nicolin, Managing Director and Chief Executive Officer

Keeping our promises

Looking back on FY17, I am pleased to report a year of achievements gained against a series of strategic goals towards which we have been working for a number of years, and with the benefits now clearly showing.


It was decided 12 months ago that there would be three key metrics against which medium-term performance would be targeted: organic revenue growth; EPS growth; and Return on Capital Employed (ROCE). Specifically for FY17, the most important objective was to realise improved organic revenue growth – and the 3.6% achieved is at the upper end of the targeted range for the year. Success was achieved through improved execution against the four key drivers of organic growth outlined opposite.


Looking to FY18 and beyond, I am confident that the right strategies are in place for Ansell to seize the opportunity to refocus on the business to business portfolio and realise the long-term value creation opportunities available.

Dividends

The Board declared a final dividend of 23.75 cents, unfranked, taking the total dividend to 44 cents per share, representing a 1.1% increase on the prior year. Record date: 21 August 2017. Dividend payment date: 8 September 2017.


Group Sales Bridge





Protection Reimagined

At Ansell, we continue to challenge ourselves on how best to serve our customers. During the next year, Ansell will be simplifying its business structure. Following the sale of the Sexual Wellness business, Ansell will merge its Single Use and Medical GBUs into a single Healthcare GBU. The Industrial GBU will remain largely unchanged. The goal is to deliver a more streamlined business proposition to customers.





GBU Results

Industrial

+5%

Sales (organic constant currency)

> **+4%** EBIT before corporate costs

Reported sales % change

7%

-10% Reported EBIT % change

Medical

+1%

Sales (organic constant currency)

> **D%** EBIT before



HyFlex

Reported sales growth

-10% Reported EBIT



+3%

Sales (organic constant currency)

-2%

EBIT before corporate costs

+6%

Reported sales growth

-2%

Reported EBIT % change

Financial Summary

	Results in Operating Currency – US Dollars	
	2016 US\$m	2017 US\$m
Sales	1,572.8	1,599.7
EBIT ¹	236.7	217.8
Profit Attributable	159.1	147.7
Operating Cash Flow ²	144.8	146.0
Earnings Per Share (US cents)	105.1	100.1
Dividends Per Share (US cents)	43.5	44.0

1. EBIT defined as Earnings Before Tax and Interest.

2. Net cash provided by operating activities per the Consolidated Statement of Cash Flows adjusted for Net Capex and interest received and paid (net interest).



Disclaimer

This annual report summary is sourced from the 2017 Ansell Annual Report and this document is intended to be a high level summary of that document. Please refer to the 2017 Ansell Annual Report for detailed definitions of each of the material terms used in this document.



Join the conversation: (in 🕑 f 🎯 🖸